Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Oncolytic Viruses: Priming Time for Cancer Immunotherapy.

Russell L, Peng KW, Russell SJ, Diaz RM.

BioDrugs. 2019 Jul 18. doi: 10.1007/s40259-019-00367-0. [Epub ahead of print] Review.

PMID:
31321623
2.

Generation of Organotypic Multicellular Spheres by Magnetic Levitation: Model for the Study of Human Hematopoietic Stem Cells Microenvironment.

Mejía-Cruz CC, Barreto-Durán E, Pardo-Pérez MA, Jimenez MC, Rincón J, Vanegas K, Rodríguez JL, Jaramillo-Garcia LF, Ulloa JC, Díaz RM, Leal-García E, Pérez-Núñez R, Barreto A, Rodríguez-Pardo VM.

Int J Stem Cells. 2019 Mar 30;12(1):51-62. doi: 10.15283/ijsc18061.

3.

Developing a modern data workflow for regularly updated data.

Yenni GM, Christensen EM, Bledsoe EK, Supp SR, Diaz RM, White EP, Ernest SKM.

PLoS Biol. 2019 Jan 29;17(1):e3000125. doi: 10.1371/journal.pbio.3000125. eCollection 2019 Jan.

4.

Parent-Initiated Sexual Orientation Change Efforts With LGBT Adolescents: Implications for Young Adult Mental Health and Adjustment.

Ryan C, Toomey RB, Diaz RM, Russell ST.

J Homosex. 2018 Nov 7:1-15. doi: 10.1080/00918369.2018.1538407. [Epub ahead of print]

PMID:
30403564
5.

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers.

Suksanpaisan L, Xu R, Tesfay MZ, Bomidi C, Hamm S, Vandergaast R, Jenks N, Steele MB, Ota-Setlik A, Akhtar H, Luckay A, Nowak R, Peng KW, Eldridge JH, Clarke DK, Russell SJ, Diaz RM.

Mol Ther Oncolytics. 2018 Jul 5;10:1-13. doi: 10.1016/j.omto.2018.05.001. eCollection 2018 Sep 28.

6.

Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.

Cunill V, Massot M, Clemente A, Calles C, Andreu V, Núñez V, López-Gómez A, Díaz RM, Jiménez MLR, Pons J, Vives-Bauzà C, Ferrer JM.

Front Immunol. 2018 May 29;9:1097. doi: 10.3389/fimmu.2018.01097. eCollection 2018.

7.

Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.

Kottke T, Evgin L, Shim KG, Rommelfanger D, Boisgerault N, Zaidi S, Diaz RM, Thompson J, Ilett E, Coffey M, Selby P, Pandha H, Harrington K, Melcher A, Vile R.

Cancer Immunol Res. 2017 Nov;5(11):1029-1045. doi: 10.1158/2326-6066.CIR-17-0175. Epub 2017 Oct 15.

8.

Coping With Sexual Orientation-Related Minority Stress.

Toomey RB, Ryan C, Diaz RM, Russell ST.

J Homosex. 2018;65(4):484-500. doi: 10.1080/00918369.2017.1321888. Epub 2017 Jun 1.

9.

[Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score].

Rio J, Rovira A, Blanco Y, Sainz A, Perkal H, Robles R, Ramio-Torrenta L, Diaz RM, Arroyo R, Urbaneja P, Fernandez O, Garcia-Merino JA, Reyes MP, Oreja-Guevara C, Prieto JM, Izquierdo G, Olascoaga J, Alvarez-Cermeno JC, Simon E, Pujal B, Comabella M, Montalban X.

Rev Neurol. 2016 Aug 16;63(4):145-50. Spanish.

10.

Core Content for Undergraduate Medical Education in Spain: Recommendations of the Instructors' Group of the Spanish Academy of Dermatology and Venereology (AEDV).

Casanova JM, Pujol RM, Ferrándiz C, Betlloch I, Bosch RJ, Fernández V, Martí RM, Requena L, Moreno JC, Alegre V, Vilata JJ, Vilar N, Jaén P, Bielsa I, Querol I, Azón T, Borrego L, Mascaró JM, Alsina M, Díaz RM, Suarez R, García-Bustinduy M, García-Patos V, Estrach T; grupo de profesores y docentes de la AEDV.

Actas Dermosifiliogr. 2016 Mar;107(2):125-32. doi: 10.1016/j.ad.2015.09.014. Epub 2015 Dec 13. English, Spanish.

PMID:
26691244
11.

Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.

Blanchard M, Shim KG, Grams MP, Rajani K, Diaz RM, Furutani KM, Thompson J, Olivier KR, Park SS, Markovic SN, Pandha H, Melcher A, Harrington K, Zaidi S, Vile R.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):577-87. doi: 10.1016/j.ijrobp.2015.07.2274. Epub 2015 Jul 26.

12.

Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

Cockle JV, Rajani K, Zaidi S, Kottke T, Thompson J, Diaz RM, Shim K, Peterson T, Parney IF, Short S, Selby P, Ilett E, Melcher A, Vile R.

Neuro Oncol. 2016 Apr;18(4):518-27. doi: 10.1093/neuonc/nov173. Epub 2015 Sep 26.

13.

Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, Shim KG, Diaz RM, Pandha H, Harrington K, Coffey M, Melcher A, Vile R.

Mol Ther. 2016 Feb;24(1):166-74. doi: 10.1038/mt.2015.156. Epub 2015 Aug 27.

14.

Being out at school: the implications for school victimization and young adult adjustment.

Russell ST, Toomey RB, Ryan C, Diaz RM.

Am J Orthopsychiatry. 2014 Nov;84(6):635-43. doi: 10.1037/ort0000037.

PMID:
25545431
15.

The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.

Alonso-Camino V, Rajani K, Kottke T, Rommelfanger-Konkol D, Zaidi S, Thompson J, Pulido J, Ilett E, Donnelly O, Selby P, Pandha H, Melcher A, Harrington K, Diaz RM, Vile R.

Mol Ther. 2014 Nov;22(11):1936-48. doi: 10.1038/mt.2014.134. Epub 2014 Jul 25.

16.

Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.

Kottke T, Boisgerault N, Diaz RM, Donnelly O, Rommelfanger-Konkol D, Pulido J, Thompson J, Mukhopadhyay D, Kaspar R, Coffey M, Pandha H, Melcher A, Harrington K, Selby P, Vile R.

Nat Med. 2013 Dec;19(12):1625-1631. doi: 10.1038/nm.3397. Epub 2013 Nov 17.

17.

Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.

Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, Embry A, Saenz D, Poeschla E, Pandha H, Harrington K, Melcher A, Selby P, Vile R.

Mol Ther. 2013 Aug;21(8):1507-16. doi: 10.1038/mt.2013.116. Epub 2013 Jun 11.

18.

CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors.

Alonso-Camino V, Sánchez-Martín D, Compte M, Nuñez-Prado N, Diaz RM, Vile R, Alvarez-Vallina L.

Mol Ther Nucleic Acids. 2013 May 21;2:e93. doi: 10.1038/mtna.2013.19.

19.

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG.

Mol Ther. 2013 Feb;21(2):348-57. doi: 10.1038/mt.2012.204. Epub 2012 Sep 25. Erratum in: Mol Ther. 2013 Apr;21(4):913. Grau, Marta C [corrected to Compte, Marta].

20.

Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.

Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kottke TJ, Vile RG.

Cancer Res. 2012 Sep 15;72(18):4753-64. doi: 10.1158/0008-5472.CAN-12-0600. Epub 2012 Jul 26.

21.

Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape.

Kaluza KM, Kottke T, Diaz RM, Rommelfanger D, Thompson J, Vile R.

Hum Gene Ther. 2012 Oct;23(10):1054-64. doi: 10.1089/hum.2012.030. Epub 2012 Aug 13.

22.

Structure, agency, and sexual development of Latino gay men.

Arreola SG, Ayala G, Díaz RM, Kral AH.

J Sex Res. 2013;50(3-4):392-400. doi: 10.1080/00224499.2011.648028. Epub 2012 Mar 21.

PMID:
22435920
23.

Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.

Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, Harrington K, Selby P, Melcher A, Vile R.

Nat Biotechnol. 2012 Mar 18;30(4):337-43. doi: 10.1038/nbt.2157.

25.

Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors.

Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R.

Nat Med. 2011 Jun 19;17(7):854-9. doi: 10.1038/nm.2390. Erratum in: Nat Med. 2012 Sep;18(9):1445.

26.

Lesbian, gay, bisexual, and transgender adolescent school victimization: implications for young adult health and adjustment.

Russell ST, Ryan C, Toomey RB, Diaz RM, Sanchez J.

J Sch Health. 2011 May;81(5):223-30. doi: 10.1111/j.1746-1561.2011.00583.x.

PMID:
21517860
27.

Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.

Wongthida P, Diaz RM, Pulido C, Rommelfanger D, Galivo F, Kaluza K, Kottke T, Thompson J, Melcher A, Vile R.

Hum Gene Ther. 2011 Nov;22(11):1343-53. doi: 10.1089/hum.2010.216. Epub 2011 Apr 11.

28.

Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba.

Morán VP, Baute RG, Facundo JC, Ramírez PH, Núñez AA, Martínez EE, Cabrera OM, Padrón CH, Otero AG, Uría JC, Estrada EE, Díaz RM, Virgil AM, Sánchez KL, Cabeza AH.

MEDICC Rev. 2011 Jan;13(1):35-40.

29.

[Acral pustules as the key manifestation in the diagnosis of subacute infective endocarditis].

Valverde R, Arranz DM, Ruiz-Bravo E, Díaz RM.

Actas Dermosifiliogr. 2010 Nov;101(9):803-5. Spanish. No abstract available.

PMID:
21034713
30.

Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.

Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):140-9. doi: 10.1038/mt.2010.224. Epub 2010 Oct 26.

31.

VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.

Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):150-8. doi: 10.1038/mt.2010.225. Epub 2010 Oct 19.

32.

Gender-nonconforming lesbian, gay, bisexual, and transgender youth: school victimization and young adult psychosocial adjustment.

Toomey RB, Ryan C, Diaz RM, Card NA, Russell ST.

Dev Psychol. 2010 Nov;46(6):1580-9. doi: 10.1037/a0020705.

PMID:
20822214
33.

Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.

Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, Pavelko K, Pease L, Melcher A, Vile R.

Cancer Res. 2010 Jun 1;70(11):4539-49. doi: 10.1158/0008-5472.CAN-09-4658. Epub 2010 May 18.

34.

Social integration and health: community involvement, stigmatized identities, and sexual risk in Latino sexual minorities.

Ramirez-Valles J, Kuhns LM, Campbell RT, Diaz RM.

J Health Soc Behav. 2010 Mar;51(1):30-47.

35.

Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.

Kottke T, Hall G, Pulido J, Diaz RM, Thompson J, Chong H, Selby P, Coffey M, Pandha H, Chester J, Melcher A, Harrington K, Vile R.

J Clin Invest. 2010 May;120(5):1551-60. doi: 10.1172/JCI41431. Epub 2010 Apr 1.

36.

Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.

Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R.

Gene Ther. 2010 Feb;17(2):158-70. doi: 10.1038/gt.2009.161. Epub 2009 Dec 17.

37.

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG.

Hum Gene Ther. 2010 Apr;21(4):439-50. doi: 10.1089/hum.2009.143.

38.

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.

Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG.

Cancer Res. 2009 Oct 1;69(19):7713-20. doi: 10.1158/0008-5472.CAN-09-1013. Epub 2009 Sep 22.

39.

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG.

Hum Gene Ther. 2009 Oct;20(10):1119-32. doi: 10.1089/hum.2009.135. Review.

40.

General and gay-related racism experienced by Latino gay men.

Ibañez GE, Van Oss Marin B, Flores SA, Millett G, Diaz RM.

Cultur Divers Ethnic Minor Psychol. 2009 Jul;15(3):215-22. doi: 10.1037/a0014613.

PMID:
19594250
41.

Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

Clin Cancer Res. 2009 Jul 1;15(13):4374-4381. doi: 10.1158/1078-0432.CCR-09-0334. Epub 2009 Jun 9.

42.

Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

Kottke T, Thompson J, Diaz RM, Pulido J, Willmon C, Coffey M, Selby P, Melcher A, Harrington K, Vile RG.

Clin Cancer Res. 2009 Jan 15;15(2):561-9. doi: 10.1158/1078-0432.CCR-08-1688.

43.

Family rejection as a predictor of negative health outcomes in white and Latino lesbian, gay, and bisexual young adults.

Ryan C, Huebner D, Diaz RM, Sanchez J.

Pediatrics. 2009 Jan;123(1):346-52. doi: 10.1542/peds.2007-3524.

PMID:
19117902
44.

Intimate partner violence and HIV sexual risk behavior among Latino gay and bisexual men: the role of situational factors.

Feldman MB, Ream GL, Díaz RM, El-Bassel N.

J LGBT Health Res. 2007;3(4):75-87.

PMID:
19042911
45.

Drug use, interpersonal attraction, and communication: situational factors as predictors of episodes of unprotected anal intercourse among Latino gay men.

Wilson PA, Díaz RM, Yoshikawa H, Shrout PE.

AIDS Behav. 2009 Aug;13(4):691-9. doi: 10.1007/s10461-008-9479-9. Epub 2008 Nov 5.

46.

Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P, Thompson J, Willmon C, Barber GN, Chester J, Selby P, Strome S, Harrington K, Melcher A, Vile RG.

Mol Ther. 2008 Dec;16(12):1910-8. doi: 10.1038/mt.2008.212. Epub 2008 Sep 30.

47.

Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.

Johnson WD, Diaz RM, Flanders WD, Goodman M, Hill AN, Holtgrave D, Malow R, McClellan WM.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001230. doi: 10.1002/14651858.CD001230.pub2. Review.

PMID:
18646068
48.

HIV infection, sexual risk behavior, and substance use among Latino gay and bisexual men and transgender persons.

Ramirez-Valles J, Garcia D, Campbell RT, Diaz RM, Heckathorn DD.

Am J Public Health. 2008 Jun;98(6):1036-42. doi: 10.2105/AJPH.2006.102624. Epub 2008 Apr 29.

49.

Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.

Kottke T, Galivo F, Wongthida P, Diaz RM, Thompson J, Jevremovic D, Barber GN, Hall G, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Mol Ther. 2008 Jul;16(7):1217-26. doi: 10.1038/mt.2008.83. Epub 2008 Apr 22.

50.

Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.

Qiao J, Wang H, Kottke T, Diaz RM, Willmon C, Hudacek A, Thompson J, Parato K, Bell J, Naik J, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Gene Ther. 2008 Apr;15(8):604-16. doi: 10.1038/sj.gt.3303098. Epub 2008 Feb 28.

Supplemental Content

Support Center